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Lung tumor metabolism is severely altered involving
enhanced levels of glucose uptake, glycolysis, lipogenesis
and protein synthesis. These events are essential for the
support of enhanced energy demands and increased
need for ribonucleotides, proteins and membrane
biogenesis that are required for rapid proliferation.
Combined treatment with cytotoxic therapy and
metabolism modulating agents may improve outcomes
in NSCLC. We observed that radiotherapy (RT) alone
activates the metabolic stress sensor AMP-activated ki-
nase (AMPK) within an Ataxia Telengiectasia Mutated
(ATM) – AMPK – p53/p21cip1 pathway to mediate the
RT-induced G2-M checkpoint and cytotoxicity. Further,
inhibition of biosynthetic pathways and energy produc-
tion through blockade of OxPhos inhibits tumor growth.
In human NSCLC cells and xenografts, we combined RT
with the anti-diabetic agent metformin, which blocks
OxPhos complex I, and showed that metformin activates
the ATM-AMPK-p53/p21cip1 axis and inhibits the Akt-
mTOR-4EBP1 pathway, tumor growth and angiogenesis
and induces apoptosis and radio-sensitization.
Based on these observations and supporting retrospec-
tive clinical evidence from locally advanced lung cancer
patients treated with Chemo-RT, we launched phase II
studies combiningmetforminwith chemo-RT. NRG-LU001
(NCT02186847) and OCOG ALMERA (NCT02186847)
are on-going randomized phase II studies investigating
whether targeting metabolism with metformin can
improve progression free survival in stage III NSCLC.
In recent studies we observed that combined treat-
ment with metabolism modulating agents can enhance
anti-tumor activity in NSCLC. Combined treatment with
Metformin and Salicylate, which activate AMPK through
different mechanisms, mediated increased inhibition of
clonogenic survival in part through AMPK and sup-
pression of de-novo lipogenesis. Further, in earlier
studies we showed that blockade of the cholesterol
synthesis pathway with lovastatin (HMG-CoA reductase
inhibitor) mediated activation of AMPK, suppression ofthe Akt-PI3k pathways and radio-sensitization of
NSCLC.
In current studies we observe that lovastatin also ac-
tivates the ATM-AMPK-p53 axis, inhibit the Akt-mTOR
pathway and mediate tumor suppression in an AMPK-
dependent manner through suppression of de novo
lipogenesis along both the mevalonate and the fatty acid
synthesis pathways. Further, in retrospective clinical
studies we ﬁnd that in locally advanced NSCLC patients
treated with Chemo-RT, statin treatment is associated
with increased survival.
These observations suggest that targeting tumor
metabolism is promising in NSCLC to improve outcomes
of standard cytotoxic therapy. Completion of on-going
trials with metformin will provide the ﬁrst prospective
evidence on this concept. We plan to investigate com-
binations of well-tolerated metabolism modulating
agents that show promising pre-clinical activity in future
rolling phase II studies.
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LA-NSCLC is frequently unresectable and is treated with
concurrent chemo-radiotherapy (CRT), which is fairly
toxic and provides poor disease control and overall
survival. There is an urgent need to develop sensitizers
to cytotoxic therapy that could improve the therapeutic
ratio in this disease.
Preclinical studies from our group and others demon-
strated that the biguanide metformin has activity in lung
cancer and sensitizes lung cancer cells and tumors to
radiotherapy and chemotherapy. Metformin is known to
induce in cells a state of mild metabolic stress through
blockade of the mitochondria OxPhos complex I. We
showed that metformin alone triggers activation of the
ATM-AMP-kinase-p53/p21cip1 pathway, inhibition of the
radio-resistance Akt-mTOR pathway, radio-sensitizes
NSCLC, enhances apoptosis and inhibits angiogenesis.
Metformin is an economical and effective anti-diabetic
agent that is well-tolerated by non-diabetics too. Based
on our pre-clinical results and additional supporting
retrospective data from stage III NSCLC patients treated
with chemo-radiotherapy, we launched a phase II clinical
trial in locally advanced NSCLC combining metformin
with concurrent CRT.
